NUNZIUM

The World Health Organization (WHO) is launching a global scientific study to update the list of priority pathogens - those microbes that can cause outbreaks and pandemics - to guide global investment, research and development (especially in vaccines), and development of tests and treatments. Starting with a meeting on Friday, November 18, WHO is convening over 300 scientists who will consider the evidence on more than 25 families of viruses and bacteria, as well as the so-called "Disease X." Disease X is a placeholder name adopted by WHO to represent a hypothetical, unknown pathogen that could cause a future international epidemic. As an outcome of the process, the experts will recommend a list of priority pathogens that need further research and investment. Both scientific and public health criteria are considered, as well as standards related to socioeconomic impact, access, and equity. The current list includes COVID-19, Crimean-Cong haemorrhagic fever, Ebola virus disease and Marburg virus disease, Lassa fever, Middle East respiratory syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), Nipah and henipaviral diseases, Rift Valley fever, Zika and Disease X. Targeting priority pathogens and virus families for research and development of countermeasures is essential for a fast and effective epidemic and pandemic response. "Without significant R&D investments before the COVID-19 pandemic, it would not have been possible to develop safe and effective vaccines in record time," said Dr Michael Ryan, Executive Director of WHO's Health Emergencies Programme. "This list of priority pathogens has become a reference point for the research community on where to focus energies to manage the next threat," said Dr Soumya Swaminathan, WHO Chief Scientist. "It is developed with experts in the field and is the agreed direction for where we - as a global research community - need to invest energy and funds to build tests, treatments and vaccines. The revised list is expected to be published in the first quarter of 2023.